GlassScriptPhysician profile
Tara Talwar
NPI 1962453761
$2,326.60
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $439 · 2021: $828 · 2022: $258.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.75 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $337.81 | 2019-2022 | |
| Pfizer INC. | $290.15 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.33 | 2019-2021 | |
| Janssen Biotech, INC. | $123.34 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $105.08 | 2021 | |
| Redhill Biopharma INC. | $101.29 | 2020-2021 | |
| Celgene Corporation | $81.35 | 2021-2022 | |
| Ucb, INC. | $72.80 | 2019-2020 | |
| Gilead Sciences, INC. | $69.87 | 2020-2021 | |
| Qol Medical, LLC | $59.41 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $58.26 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $51.27 | 2019-2020 | |
| Amgen INC. | $49.50 | 2021 | |
| Allergan, INC. | $20.84 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $20.12 | 2019 | |
| Intercept Pharmaceuticals, INC. | $15.22 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.21 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Talwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.